< Back to topics
> Cover Page, Authors, Institutions
> Purpose/Objective
> Materials/Methods
> Results/Discussion
> Conclusions
> View tables/images/videos
> View abstract & virtual poster in original format
|
|
Results:
The actuarial 10-year Freedom from PSA Failure (FFPF) was 96%. The total number of patients who failed was 15. The median 5-year PSA was 0.03ng/mL, with a range of 0-3.6. The distribution of 5-year PSA values was: ≤0.01 - 47.5%, >0.01-0.10 - 29%, >0.10-0.2 - 10.5%, >0.2-0.5 - 8%, >0.5 - 5%. The 5-year PSA value had prognostic significance, with values of <0.1 (n=465) and ≥0.1 (n=263) corresponding to actuarial 10-year freedom from PSA failure rates of 99.5% and 90.5%, respectively (p<0.0001). The PSA at the time of initial diagnosis also had prognostic significance, with values of ≤10 (n=497), >10-20 (n=155), and >20 (n=56) corresponding to actuarial 10-year freedom from PSA failure rates of 97%, 97.5%, and 83%, respectively (p=0.002). Stage (actuarial 10-year FFPF ≤T2a=95%, ≥T2b=96%, p=0.53), grade (actuarial 10-year FFPF ≤6=96%, 7=94%, 8-10=96%, p=0.34), and BED value (actuarial 10-year FFPF ≤180=92%, >180=99%, p=0.113) did not have prognostic significance. In the 15 patients who failed, the median PSA doubling time was 9 months, with a range of 1.7-30 months. None of the 708 patients in this study developed metastatic disease or died due to prostate cancer.
|
|
